Fosamprenavir (Lexiva, Telzir): News & Research

Clinical Trials Using Fosamprenavir (Lexiva) (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health
Fosamprenavir Pediatric Dosing Approved in U.S. for Ages 4 Weeks to <6 Years (May/June 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
New Pediatric Lexiva Dosing Regimen for Patients From at Least 4 Weeks to Less Than 6 Years of Age (April 27, 2012)
From U.S. Food and Drug Administration
Pharmacokinetics of Darunavir and Fosamprenavir in Pregnancy (July/August 2011)
To read PDF, click here.
FDA: HIV Drug Lexiva Label to Warn of Cholesterol Increases (December 4, 2009)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from CDC National Prevention Information Network
GlaxoSmithKline Announces New Program to Provide Financial Assistance for Eligible HIV Patients in the U.S. (November 11, 2008)
If you live in the United States, use private health insurance and take Combivir (AZT/3TC), Epzicom (abacavir/3TC, Kivexa), Lexiva (fosamprenavir, Telzir) or another HIV drug made by GlaxoSmithKline, you may have a chance to save a nice chunk of change.
From GlaxoSmithKline
New Dosing Regimen for Lexiva Approved (October 12, 2007)
From U.S. Food and Drug Administration
Agenerase (Amprenavir) Oral Solution and 50-mg Capsules to Be Discontinued in the U.S. (October 2007)
To read PDF, click here.
From GlaxoSmithKline
FDA Approval of Lexiva Oral Suspension and Label Changes for Pediatric Patients and Patients With Hepatic Impairment (June 18, 2007)
From U.S. Food and Drug Administration
Fosamprenavir Efficacy and Safety on Par With Other PIs, With No Gender-Based Differences (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Potency of Boosted Fosamprenavir Matches Lopinavir/Ritonavir for First-Line Therapy (August 17, 2006)
In XVI International AIDS Conference
Pharmacokinetic Data Show That Fosamprenavir + Atazanavir Combination Should Not Be Used (February 6, 2006)
However, boosting with atazanavir instead of ritonavir does appear feasible, this study finds.
In The 13th Conference on Retroviruses and Opportunistic Infections
Rare Case of Protease Inhibitor Resistance After Failure of First-Line Boosted Fosamprenavir (December 17, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
Fosamprenavir + Ritonavir Appears Safe Through 120 Weeks in HIV/HBV and HIV/HCV-Coinfected Patients (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Lexiva: Blood Levels Not Lowered When Taken Simultaneously With Esomeprazole (Nexium) (June 20, 2005)
In AIDS Treatment News, from AIDS Treatment News
Don't Combine Fosamprenavir and Lopinavir/Ritonavir (February/March 2005)
From TheBodyPRO.com
Boosted Fosamprenavir Works Well as First-Line Therapy (July 23, 2004)
A HAART regimen containing fosamprenavir and ritonavir is highly effective and well-tolerated when used as first-line therapy in patients with advanced HIV, according to the final published results from this major study.
In AIDS
Fosamprenavir Update (July 13, 2004)
Recaps of studies on treatment-naive patients, switching from amprenavir and fosamprenavir resistance.
In The XV International AIDS Conference, from TheBodyPRO.com
Lexiva + Kaletra -- Still a Bad Idea (March/April 2004)
A short review of a study presented at CROI 2004.
In Positively Aware, from Positively Aware
The NEAT Study: A 48-Week Open-Label Study to Compare the Antiviral Efficacy and Safety of GW433908 Versus Nelfinavir in Antiretroviral Therapy-Naive HIV-1-Infected Patients (January 2004)
In Journal of Acquired Immune Deficiency Syndrome
Summary of Fosamprenavir Studies on Treatment-Naive and Protease Inhibitor-Experienced Patients (November 2003)
In IAPAC Monthly, from International Association of Physicians in AIDS Care

1 | 2 Next >